New study provides insight in identifying, treating lung cancer at early stages
(Boston University School of Medicine) Lung carcinomas are the leading cause of cancer-related deaths in the United States and worldwide. Lung squamous cell carcinomas (non-small cell lung cancers that arise in the bronchi of the lungs and make up approximately 30 percent of all lung cancers) are poorly understood, particularly with respect to the cell type and signals that contribute to disease onset. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news
Response to Comment on "Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression"
Kamphuis et al. argue that macrophages accumulated in the proximity of tumor-initiating cells do not express the high-affinity immunoglobulin E receptor FcRIα. Although we cannot exclude the possibility of nonspecific binding of anti-FcRIα antibody (clone MAR-1), we provide evidence that macrophages in squamous cell carcinomas express FcRIα and that IL-33 induces FcRIα expression in bone marrow cell–derived macrophages. (Source: ScienceNOW)
Source: ScienceNOW - April 8, 2021 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J., Oshimori, N. Tags: Immunology, Medicine, Diseases t-comment Source Type: news
Actinic Keratosis Diagnosis Ups Cumulative Risk for Skin Cancer
MONDAY, March 29, 2021 -- The annual increase in risk for cutaneous squamous cell carcinoma (cSCC) is higher for patients who have received a diagnosis of one or more actinic keratoses (AKs), according to a study published online March 24 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2021 Category: Pharmaceuticals Source Type: news
Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings, published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses the body ...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news
2020 British Guidelines for Cutaneous Squamous Cell Carcinoma 2020 British Guidelines for Cutaneous Squamous Cell Carcinoma
Review a summary of the latest updates regarding clinical management of cutaneous squamous cell carcinoma, as presented in the 2020 guidelines from the British Association of Dermatologists.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news
Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
(Impact Journals LLC) In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: news
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
A Phase II ... Biopharmaceuticals, Oncology, Licensing Merck KGaA, Debiopharm, xevinapant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2021 Category: Pharmaceuticals Source Type: news
How Serious Is A Squamous Cell Carcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 1, 2021 Category: General Medicine Source Type: news
GERD Linked to Squamous Cell Cancers of Larynx, Esophagus
MONDAY, Feb. 22, 2021 -- Gastroesophageal reflux disease (GERD) appears to be associated with an increased risk for squamous cell cancers of the larynx and esophagus, according to a study published online Feb. 22 in Cancer.
Shao-Ming Wang, Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2021 Category: Pharmaceuticals Source Type: news
Expert Offers Tips for Sorting Out Pink Lesions on Dermoscopy Expert Offers Tips for Sorting Out Pink Lesions on Dermoscopy
"How can dermoscopy help us distinguish between Spitz nevus, melanoma, clear cell acanthoma, psoriasis, basal cell carcinoma, and squamous cell carcinoma?"Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 2, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
Gene Test Helps Inform Management of High-Risk SCC Patients Gene Test Helps Inform Management of High-Risk SCC Patients
Emerging data support the clinical validity and use of DecisionDx-SCC as a prognostic 40-gene expression profile test for patients with high-risk squamous cell carcinoma.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 1, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Cemiplimab for advanced cutaneous squamous cell carcinoma: survival gains at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news
